Stuart Therapeutics adds recognized leaders in ophthalmic therapeutics development, commercialization.
STUART, Fla., December 22, 2024 /PRNewswire/ — Stuart Therapeutics announced today the hiring of Tracy Valorie and Jason Werner to the company's Board of Directors, bringing the total number of Board members to five. The new Directors will hold positions that were previously held Robert O. BarattaMD, who died suddenly in the third quarter of this year, and a retired US Representative Diane Black, RNwho recently resigned from his position on the company's Board.
Tracy Valorie is a professional business consultant and owner of ™V Associates LLC since July 2019. Miss Valorie has 30 years of experience in the pharmaceutical and biologics industry. Miss Valorie served as senior vice president, general manager of US the pharmaceutical and surgical businesses of Bausch + Lomb from July 2012 to go May 2019. Prior to joining B+L in 2012, Miss Valorie served as the commercial leader of ophthalmology in Pfizer Inc. (NYSE: NYSE:) where he had global responsibility for ophthalmology brands and responsibility for commercial development of the mid-level portfolio and long-term strategic planning. He currently works as a consultant or board member for several start-up companies and was recently named to the Board of Directors of the Glaucoma Research Foundation (GRF). Miss Valorie He has a Master of Business Administration from Rensselaer Polytechnic Institute and a Bachelor of Science in Molecular Biology from the University of Connecticut at the Storrs, CT.
Jason Werner he currently serves as the Executive Chairman of Sightstream Biotherapeutics, a biotechnology company focused on developing innovative treatments in Ophthalmics and is a member of the Board of Directors of InflammX Therapeutics. In addition, Mr. Werner served as a director of Alimera (NASDAQ: ) since Q2 2023 before joining Alimera's management team in Q4 2023 and then helped lead the company through its recent sale to ANI Pharma in Q4-2024. Mr. Werner previously established and served as Chief Operating Officer of Eyevance Pharmaceuticals from the establishment of the company through its sale to Santen Pharmaceuticals Ltd. He has also held various commercial development roles and business strategy positions in companies such as Sun Pharma, Nicox (EPA:) SA together Encourage medicationall within the field of ophthalmology. Mr. Werner received his BS in business administration from University of New Hampshire.
“We are excited about the opportunity to bring Tracy and Jason as members of our Board of Directors and senior advisors to Stuart Therapeutics as we transition into our next phase of development and commercialization of ophthalmology therapeutics,” he said. Eric Smurf, Stuart's President and CEO. “Our team will benefit from the successful experience he brings to our organization. We would also like to thank the contribution of our friend and founder. Bob BarattaMD, and Diane Black, RNwho were instrumental in guiding the company through its stages, and we wish Diane the best in her future endeavors.”
“I am excited to join the board of directors at Stuart Therapeutics. The opportunity to contribute to such a biotech company leading the way in groundbreaking treatments is truly exciting. I look forward to working with an amazing team, to help lead the company as it continues to make a meaningful impact in the lives of patients diagnosed with untreated eye problems, ” he said Tracy Valorie.
Jason Werner said, “This is an exciting time for Stuart Therapeutics with key developments and pipeline appointments at the stage. I look forward to working with Tracy and Eric and the rest of the talented team in helping to ensure that these novel therapies make their way to patients while maximizing shareholder value in Stuart and its investors. “
About Stuart Therapeutics, Inc.
Stuart Therapeutics, Inc. is a clinical stage ophthalmic development company, based in Stuart, Florida. The company's main asset, ST-100, is in the final phase of its Phase 3 clinical trial, and is expected to study in the first quarter of 2025. Stuart also develops lead programs in retinal disease and myopia and has a licensed development partnership for neuroprotection in glaucoma and The Glaukos Company (NYSE: ). of the Aliso Viejo, California.
Media contact:
Eric Smurf
President and CEO
eric@stuarttherapeutics.com
206-228-2781
www.stuarttherapeutics.com
